The Testosterone Trials in Older Men: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for The Testosterone Trials in Older Men (NCT00799617), a randomized phase 3 study. The primary outcome is Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12.

2. Clinical Question

3. Trial Design

The Testosterone Trials in Older Men are recorded as a Phase 3, randomized, parallel-group study comparing AndroGel® testosterone gel with placebo gel. The registry record identifies quadruple masking. It does not specify which participants, clinicians, assessors, or other groups were masked, so the label alone cannot establish the exact masking arrangements.

The planned enrollment was 790. The study is described as a multi-center set of trials involving 12 clinical sites geographically distributed across the United States. The sponsor was the University of Pennsylvania. The recorded start was 2009-11, the primary completion was 2014-07, and the status is COMPLETED.

The overall program was described as seven coordinated testosterone treatment trials. Its aims addressed abnormalities in areas that could be related to low testosterone, including physical or sexual function, vitality, cognition, and anemia. The summary also describes a Cardiovascular Trial and a Bone Trial incorporated into the program. The Cardiovascular Trial was intended to examine cardiovascular risk factors, and the Bone Trial was intended to assess lumbar-spine volumetric trabecular bone mineral density using quantitative computed tomography. A pharmacokinetic study was also described, examining variation in serum testosterone concentration after gel application four months after treatment began.

The posted primary endpoint belongs to the Sexual Function Trial. The registry record lists secondary outcomes in sexual function, physical function, and vitality. It does not establish that every aim or component of the broader program shared the same endpoint, analysis population, or follow-up schedule. Details beyond those recorded, including the specific randomization procedure and the full operational masking plan, are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Main Testosterone Trial

Reasons for not completing this period:

Sexual Funtion Trial

Reasons for not completing this period:

Physical Function Trial

Reasons for not completing this period:

Vitality Trial

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Two participants were randomized in error, one in each arm of the study.

6. Primary Endpoint

The registry lists the primary outcome as Sexual Function Trial - Change in Psychosexual Daily Questionnaire Question 4 (PDQ-Q4) From Baseline to Month 12, measured over 1 year (change from baseline to month 3, 6, 9 and 12).

The primary endpoint is change from baseline to Month 12 in responses to Question 4 of the Psychosexual Daily Questionnaire, or PDQ-Q4. The question covers sexual activity, and the score ranges from 0 to 12. Higher scores indicate more activity. The endpoint is a continuous measure, and the registry record identifies the planned summary as a mean with a standard deviation.

A questionnaire measure can capture a participant’s reported experience in a way that a laboratory measurement may not. In this trial, the PDQ-Q4 provides a structured measure of sexual activity for the Sexual Function Trial. Looking at change from baseline is intended to describe how scores vary over the study period, rather than only describing scores at one time point. The stated timeframe includes change from baseline at months 3, 6, 9, and 12, while the primary endpoint title focuses on Month 12.

The scale’s direction is important when interpreting any change: a higher score represents more activity. However, the registry record does not report the arm-specific mean changes, the between-group contrast, or its uncertainty for this endpoint. The listed outcome description alone therefore identifies what was measured, not the magnitude or direction of the observed comparison.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry record describes a randomized, parallel-group comparison. In a randomized trial, assignment is intended to make the groups comparable at the time of allocation, on average, by using chance rather than choosing treatment according to participant characteristics. This design can support a causal comparison when the analysis and follow-up preserve the benefits of randomization. The record does not report the specific sequence-generation or allocation-concealment methods, so those details cannot be evaluated from this entry.

What does a mean change represent?

The primary measure is continuous, and the registry identifies the mean and standard deviation as its summary. A mean describes the average score or change across participants included in a calculation. The standard deviation describes how dispersed individual values are around that mean. It is not the same as uncertainty in the estimated mean or in a difference between groups. A wide spread among participants can coexist with a precisely estimated group mean when enough observations contribute, while missing observations or a limited number of participants can reduce precision.

For a treatment comparison, the central quantity is generally the contrast between the groups, not the change in one group alone. Both groups can change over time, so a within-group change does not by itself isolate the difference associated with assignment. The registry record does not report the arm-specific means or the between-group estimate for the primary endpoint; no such contrast can be interpreted from the endpoint definition alone.

How should confidence intervals and p-values be read?

In general, a confidence interval expresses the uncertainty around an estimated quantity under the assumptions of the statistical method. Its width reflects precision: a narrower interval indicates greater precision than a wider interval for the same type of estimate. The interval also shows which values are compatible with the data and method at the stated confidence level. A p-value, in general, describes how unusual data at least as inconsistent with a specified null model would be if that model and the analysis assumptions held. It is not the probability that the null hypothesis is true, nor does it measure the size or clinical importance of an effect.

Neither a confidence interval nor a p-value for the primary endpoint is reported in the registry record. Without an estimate and its uncertainty, the evidence cannot be characterized as precise or imprecise, and the endpoint’s scale alone cannot establish a treatment-group difference.

Why do allocation and masking matter?

Random allocation can reduce systematic differences between groups at baseline. Masking can reduce the chance that knowledge of assignment affects behavior, assessment, or reporting. The registry label is quadruple masking, but the record does not identify the masked groups or explain how masking was maintained. It also does not report whether masking was assessed during the trial. These are limits on judging the practical protections against bias from the registry entry alone.

The parallel-group structure means the record describes participants allocated to one of the study arms, rather than a planned crossover in which participants receive both treatments. The stated interventions were testosterone gel and placebo gel. Details such as adherence summaries, treatment discontinuation, and the handling of participants who changed or stopped assigned treatment are not reported in the registry record.

What can planning calculations tell readers?

In general, sample-size planning illustrations use assumptions about the effect to be detected, variability, significance level, allocation, and statistical model. A planning illustration is not a trial result and is not “observed power.” Power is a design property calculated before observing results under specified assumptions; calculating power from an observed effect does not provide a useful substitute for the estimated effect and its confidence interval. The record describes planning illustrations using a two-sided significance level of 0.05, equal allocation, and a normal approximation, with the target effect set as a stated fraction of an observed effect. It also distinguishes participants per arm for most outcomes from total events for time-to-event outcomes. No further conclusion about the trial’s own design justification should be drawn from those planning assumptions: the registry record does not report the trial’s sample-size justification.

More generally, statistical interpretation depends on the outcome definition, the analysis population, the model, missing-data handling, and multiplicity procedures as well as the numerical estimate. Those details are not all described in the registry record. The method label for a continuous mean does not by itself establish how baseline values, repeated measurements, or incomplete observations were handled.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists 37 outcome measures and 37 analyses. It also describes several clinical aims and secondary outcomes across sexual function, physical function, and vitality. When a study evaluates many outcomes, time points, or statistical comparisons, the chance of at least one apparently unusual result can increase if each test is interpreted in isolation. General approaches to multiplicity include prespecifying a hierarchy, adjusting significance thresholds, or treating results as exploratory. Which approach was used for these outcomes is not reported in the registry record.

The primary endpoint description refers to change at months 3, 6, 9, and 12, while its title identifies Month 12. The record also states that the primary outcome has several categories or time points and is not reduced to one comparison. The statistical plan for selecting or combining time points, and the way the different components were analyzed, are not reported in the registry record. The primary outcome’s numerical results are also not reported in the registry record.

Missing outcome data can affect both the number of participants contributing to an analysis and the comparability of the groups. In general, methods may use observed cases, model-based approaches, imputation, or other strategies, each relying on assumptions about why values are missing. The registry record does not report the amount or pattern of missing primary-outcome data, the method used to address missingness, or sensitivity analyses. It also does not report the analysis populations, such as whether the primary analysis followed original randomized assignment or used another defined group. These omissions limit assessment of how the reported analyses relate to the randomized design.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cardiac disorders (8.9%), infections and infestations (7.4%), musculoskeletal and connective tissue disorders (5.6%), nervous system disorders (5.6%), respiratory disorders (4.3%).

The registry record lists 394 participants at risk in each arm for serious adverse events. It lists 183 participants affected in the AndroGel® group and 176 in the placebo-gel group. For other adverse events, it lists 343 participants affected in the AndroGel® group and 341 in the placebo-gel group, with 394 at risk in each arm. These figures are counts, not adjusted estimates of a difference between treatments. The registry record does not report uncertainty intervals or a statistical comparison for these counts.

The serious adverse-event terms listed include Cardiac disorders at 8.9%, Infections and infestations at 7.4%, Musculoskeletal and connective tissue disorders at 5.6%, Nervous system disorders at 5.6%, Respiratory disorders at 4.3%, and Neoplasms benign, malignant and unspecified at 3.8%. The record does not specify the denominator for these percentages or assign these term percentages to a particular arm. The terms therefore should not be read as arm-specific risks from the information recorded.

Deaths are not reported in the registry record. The record also does not provide enough detail to determine event timing, treatment relatedness, recurrence, or the rules used to classify and group events. Counts alone do not establish a causal relationship to an intervention.

12. What the Result Does, and Does Not, Mean

The record describes a randomized, masked comparison of testosterone gel and placebo gel among older men selected for low serum testosterone and related symptoms or abnormalities. It identifies a primary measure of sexual activity and lists additional outcomes and safety counts. Those details characterize the study question and some of the reported information, but they do not answer the primary question numerically.

The primary endpoint is a questionnaire score with a defined range and direction. To interpret the study’s result, readers would need the group-specific changes and the between-group contrast, together with an estimate of uncertainty. Those primary-endpoint results are not reported in the registry record. Without them, the direction and magnitude of the observed contrast, and the precision of that estimate, cannot be described.

The adverse-event counts provide a descriptive account of the number of participants affected in each group. They do not, by themselves, establish whether an event was caused by treatment or whether the observed counts represent a meaningful difference. The registry record does not report deaths, an adjusted safety analysis, or uncertainty measures for the listed counts.

In general, a trial’s results apply most directly to the population, interventions, outcomes, follow-up, and analytic methods actually studied. The stated target population and the broader program’s multiple aims do not establish that findings from one outcome apply to all other outcomes or populations. The registry entry does not provide enough detail to assess all eligibility criteria, missing-data methods, or analysis populations.

These limits do not imply that there was no effect, nor do they establish that there was one. They mean that the registry information recorded is insufficient to quantify the primary comparison or evaluate its statistical uncertainty. No clinical recommendation follows from the design description or the adverse-event counts alone.

13. Why This Trial Matters Statistically

This trial is statistically notable for asking a set of related questions across several domains rather than relying on a single type of measurement. The record describes physical or sexual function, vitality, cognition, anemia, cardiovascular risk factors, bone density, and pharmacokinetic variability as areas of interest. It also lists a range of secondary outcomes. Such breadth makes clear why outcome definitions and analysis plans matter: different measures can address distinct questions and may not be combined into one overall conclusion.

The primary sexual-function endpoint uses a questionnaire score with a defined range and direction, and the registry identifies mean change as its summary. That gives readers a clear description of the measurement, but a measurement definition is only one part of statistical evidence. The estimate between arms, its uncertainty, the analysis population, and the handling of repeated time points are also needed to assess the result.

The record’s count of 37 outcome measures and 37 analyses highlights the importance of multiplicity. When many outcomes are examined, a clear distinction between prespecified primary questions and other analyses helps readers judge how much weight to place on individual findings. The registry entry does not report the multiplicity strategy, so that aspect of interpretation remains unresolved.

The study also illustrates the difference between a trial’s design and its available results. Randomization, masking, and a placebo comparator describe how a comparison was organized; they do not substitute for an outcome estimate. The record identifies a completed study and provides safety counts, but it does not report numerical results for the named primary endpoint. Statistically, the absence of an effect estimate and precision measure prevents evaluation of the primary contrast from this record alone.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry record does not report numerical results for the primary endpoint, including mean changes by arm, the between-group contrast, a confidence interval, or a p-value. This prevents assessment of the endpoint’s estimated direction, size, and precision. The endpoint description identifies a Month 12 focus while also naming measurements at months 3, 6, 9, and 12; the analysis approach for those time points is not reported in the registry record.

The broader program includes several aims and the record lists 37 outcome measures and 37 analyses, but the multiplicity strategy and the relationship among the analyses are not reported. The analysis populations, missing-data amount and handling, adherence, and treatment discontinuation are also not reported in the registry record. Those details are needed to assess how the analyses relate to randomized assignment and whether incomplete observations could affect interpretation.

The design labels do not provide every operational detail. Although the registry record identifies randomization and quadruple masking, the allocation procedure and the specific groups masked are not reported. Eligibility criteria beyond the broad description, baseline characteristics, and the primary endpoint’s numerical distribution are not reported in the registry record.

Safety reporting is also limited. Counts of participants affected are listed, but uncertainty estimates, statistical comparisons, event attribution, timing, and death counts are not reported. The record lists serious-event term percentages without specifying their denominator or linking them to an arm. These limitations mean the safety figures can be described as recorded counts, but not interpreted as a complete causal or comparative safety assessment.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: The Testosterone Trials in Older Men — NCT00799617.
• Registry record last updated 2019-02-21; status last verified 2019-02.
• Results first posted 2017-08-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The Testosterone Trials in Older Men are recorded as a completed, randomized, parallel-group Phase 3 study sponsored by the University of Pennsylvania. The planned enrollment was 790, and the record describes 12 clinical sites across the United States. The interventions were AndroGel® testosterone gel and placebo gel; masking is recorded as quadruple.

The primary outcome was change in PDQ-Q4 score from baseline to Month 12. The scale ranges from 0 to 12, with higher scores indicating more sexual activity. Numerical results for this primary comparison are not reported in the registry record. The record lists adverse-event counts of 183 and 176 participants affected by serious adverse events in the testosterone and placebo groups, respectively, and 343 and 341 affected by other adverse events. Deaths are not reported in the registry record.